Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response.

JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. Abstract Text:

    jian taoJian Tao,yunfei gaoYunfei Gao,ming o liMing O Li,weifeng heWeifeng He,liang chenLiang Chen,bohdan harvevBohdan Harvev,roger j davisRoger J Davis,richard a flavellRichard A Flavell,zhinan yinZhinan Yin,

    JNK1 and JNK2 have distinct effects on activation, differentiation and function of CD8+ T cells. Our early studies demonstrated that JNK1 is required for CD8+ T cell-mediated tumor immune surveillance. However, the role of JNK2 in CD8+ T cell response and effector functions, especially in anti-tumor immune response, is unknown. To define the role of JNK2 in antigen-specific immune response, we have investigated CD8+ T cells from OT-1 CD8+ transgenic mice in response to either high- or low-affinity peptides. JNK2-/- CD8+ T cells proliferated better in response to both peptides, with more cell division and less cell death. In addition, JNK2-/- CD8+ T cells produced higher levels of IFN-gamma, which is associated with increased expression of T-bet and Eomesodermin (Eomes). Moreover, JNK2-/- CD8+ T cells expresses high levels of granzyme B and show increased CTL activity. Finally, the enhanced expansion and effector function of JNK2-/- CD8+ T cells was further evidenced by their capacity to delay tumor growth in vivo. In summary, our results demonstrate that JNK2 negatively regulates antigen-specific CD8+ T cell expansion and effector function, and thus selectively blocking JNK2 in CD8+ T cells may potentially enhance anti-tumor immune response.

    JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. Publishing Authors By Initials

    j taoJ Tao,y gaoY Gao,mo liMO Li,w heW He,l chenL Chen,b harvevB Harvev,rj davisRJ Davis,ra flavellRA Flavell,z yinZ Yin,

    For similar enzymes and coenzymes: enzymes: transferases: phosphotransferases: phosphotransferases (alcohol group acceptor): protein kinases: protein-serine-threonine kinases: mitogen-activated protein kinases: jnk mitogen-activated protein kinases: mitogen-activated protein kinase 9 research abstracts see: enzymes and coenzymes: enzymes: transferases: phosphotransferases: phosphotransferases (alcohol group acceptor): protein kinases: protein-serine-threonine kinases: mitogen-activated protein kinases: jnk mitogen-activated protein kinases: mitogen-activated protein kinase 9 research

    PUBMED ID PMID:

    MEDLINE DATE:

    JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: European journal of immunology

    VOLUME: 37

    Page Numbers: 818-29

    Journal Abbreviation: Eur. J. Immunol.

    ISSN: 0014-2980

    DAY: 3

    MONTH: Mar

    YEAR: 2007

    JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 1273201

    JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. Keywords Mesh Terms:

    KEYWORDS: Mitogen-Activated Protein Kinase 9

    MESH TERMS: physiology

    Chemical & Substance for Abstract: JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. Information

    Substance Name: Mitogen-Activated Protein Kinase 9

    Registry Number: EC 2.7.1.37

    Grant and Affiliation Information for JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response.

    AFFILIATION: Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT 06520-8031, USA.

    Country: Germany

    Germany Research PublicationGermany Research Publication

    AGENCY: United States NIAID

    GRANT: R01AI56219

    ACRONYM: AI

    MEDLINETA: Eur J Immunol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News